EHA 2022 Conference Coverage

 

MDS and MPN
30

EHA 2022 Conference Coverage

Lecture Summary - EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magrolimab

FEATURING David Sallman
  • 15 views
  • August 4, 2022
06:24

EHA 2022 Conference Coverage

EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magrolimab

FEATURING David Sallman
  • 391 views
  • August 4, 2022
30

EHA 2022 Conference Coverage

[private] Lecture Summary - EHA 2022 on ENHANCE Study: A Randomized Phase 3 Study on Magrolimab + Azacitidine vs Azacitidine + Placebo in Untreated HR-MDS

FEATURING David Sallman
  • 5 views
  • August 3, 2022
06:24

EHA 2022 Conference Coverage

[private] EHA 2022 on ENHANCE Study: A Randomized Phase 3 Study on Magrolimab + Azacitidine vs Azacitidine + Placebo in Untreated HR-MDS

FEATURING David Sallman
  • 2 views
  • August 3, 2022
04:48

EHA 2022 Conference Coverage

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Higher-Risk MDS: 5F9005 Phase 1b Study Results

FEATURING David Sallman
  • 247 views
  • June 22, 2022
31

EHA 2022 Conference Coverage

Lecture Summary - EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Higher-Risk MDS: 5F9005 Phase 1b Study Results

FEATURING David Sallman
  • 6 views
  • June 22, 2022
06:43

EHA 2022 Conference Coverage

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated HR-MDS: 5F9005 Phase 1b Study Results

FEATURING Uwe Platzbecker
  • 11 views
  • June 21, 2022